

Exhibit 22

2013 WL 1558690
NOT FOR PUBLICATION
United States District Court, D. New Jersey.

In re FOSAMAX (ALENDRONATE SODIUM)
PRODUCTS LIABILITY LITIGATION.
Bernadette Glynn and Richard Glynn, Plaintiffs,
v.
Merck Sharp & Dohme Corp, Defendant.

Civil Action Nos. 11–5304, 08–08.
|
April 10, 2013.

Attorneys and Law Firms

Donald A. Ecklund, James E. Cecchi, Carella Byrne Cecchi Olstein Brody & Agnello, P.C., Roseland, NJ, Christopher A. Seeger, David R. Buchanan, Seeger Weiss, LLP, Newark, NJ, Edward Braniff, Weitz & Luxenberg, New York, NY, for Plaintiffs.

David J. Heubeck, Venable LLP, Baltimore, MD, Karen A. Confoy, Fox Rothschild LLP, PC, Lawrenceville, NJ, for Defendant.

OPINION

PISANO, District Judge.

*1 Plaintiffs Bernadette Glynn and Richard Glynn (“Plaintiffs”) bring this lawsuit against Defendant Merck, Sharp, & Dohme Corp. (“Defendant”), which manufactures Fosamax, a drug approved by the United States Food and Drug Administration (“FDA”) for the treatment and prevention of osteoporosis. This matter is part of the multi-district litigation concerning Fosamax and involves allegations that Fosamax causes atypical femur fractures (“AFFs”¹) and that it caused Plaintiff Mrs. Glynn (“Mrs. Glynn”)’s femur fracture. Presently before the Court is Defendant’s Omnibus *Daubert* Motion to exclude the expert testimony of Dr. Charles N. Cornell (“Dr. Cornell”), Dr. Michael J. Klein (“Dr. Klein”), Dr. David Madigan (“Dr. Madigan”), and Dr. Cheryl Blume (“Dr. Blume”) as well as a motion to exclude the causation testimony of the treating physicians—Dr. Robert Busch (“Dr. Busch”), Dr. Robert Lindsay (“Dr. Lindsay”), Dr. Frederick Fletcher (“Dr. Fletcher”), and Dr. Britton Limes (“Dr. Limes”) [docket

28]. This Court heard oral argument on February 21, 2013 and April 2, 2013. For the reasons outlined below, the Motion is denied as to Drs. Cornell, Klein, Madigan, and Blume. The treating physicians’ causation testimony will not be excluded if their opinions are based on their treatment and care of Mrs. Glynn.

I. DISCUSSION

Federal Rule of Evidence 702 provides that a witness





qualified as an expert by knowledge, skill, experience, training, or education may testify in the form of an opinion or otherwise if:





- (a) the expert’s scientific, technical, or other specialized knowledge will help the trier of fact to understand the evidence or to determine a fact in issue;
- (b) the testimony is based on sufficient facts or data;
- (c) the testimony is the product of reliable principles and methods; and
- (d) the expert has reliably applied the principles and methods to the facts of the case.



This Rule requires the proponent of expert testimony to show the “requisite ‘qualifications, reliability, and fit’ ” or in other words, that “(1) the witness is qualified as an expert in a particular field; (2) the methodology applied by the witness is sufficiently reliable; and (3) the witness’s testimony ‘fits’ the facts of the case in dispute—that is, the proffered testimony would assist the trier of fact.” *Jones v. Synthes USA Sales, LLC*, 2010 WL 3311840, *4 (D.N.J. Aug. 19, 2010); see also *McNamara v. Kmart Corp.*, 380 Fed. Appx. 148, 151 (3d Cir. 2010); *Meadows v. Anchor Longwall & Rebuild, Inc.*, 306 Fed. Appx. 781, 788 (3d Cir. 2009); *Pineda v. Ford Motor Co.*, 520 F.3d 237, 244 (3d Cir. 2008); *Schneider ex rel. Estate of Schneider v. Fried*, 320 F.3d 396, 404 (3d Cir. 2003).

First, the expert must be qualified; this requirement is interpreted liberally and “a broad range of knowledge, skills, and training qualify an expert as such.” *In re Paoli R.R. Yard PCB Litigation*, 35 F.3d 717, 741 (3d Cir. 1994).

*2 Second, “an expert’s testimony is admissible so long as the process or technique the expert used in formulating

the opinion is reliable.”  *Id.* at 742. An expert’s opinion is reliable if it is “based on ‘good grounds,’ i.e., if it is based on the methods and procedures of science.”  *Id.* at 744. This inquiry requires a court to examine the “scientific validity and thus the evidentiary relevance and reliability [] of the principles that underlie a proposed submission” and to focus “solely on principles and methodology, not on the conclusions ... [the expert] generate[s].”  *Daubert v. Merrell Dow Pharmaceuticals, Inc.*, 509 U.S. 579, 594–95, 113 S.Ct. 2786, 125 L.Ed.2d 469 (1993). In *Daubert*, the Supreme Court outlined several factors that a court may take into consideration in determining reliability, including whether the hypothesis can be tested, whether the methodology “has been subjected to peer review and publication,” the methodology’s rate of error, “the existence and maintenance of standards controlling the technique’s operation,” and whether there is general acceptance in the scientific community. *Id.* at 593–94. The proponent of the expert testimony must demonstrate that the opinions are reliable by a preponderance of the evidence.  *In re Paoli*, 35 F.3d at 744.






Third, expert testimony “must fit the issues in the case” or in other words, “be relevant for the purposes of the case and must assist the trier of fact.”   *Schneider*, 320 F.3d at 404. The Court must determine “whether [the] expert testimony proffered ... is sufficiently tied to the facts of the case that it will aid the jury in resolving a factual dispute.”  *United States v. Schiff*, 602 F.3d 152, 173 (3d Cir.2010). This standard “is not that high” but “higher than bare relevance.”  *In re Paoli*, 35 F.3d at 745.

The Court’s role, at a *Daubert* hearing, is to act “as a gatekeeper, preventing opinion testimony that does not meet the requirements of qualification, reliability and fit from reaching the jury.”   *Schneider*, 320 F.3d at 404. In keeping with its gatekeeping role, this Court will apply the *Daubert* analysis to each expert.

A. Dr. Cornell

Plaintiffs offer Dr. Cornell, an orthopedist, as an expert in causation, to establish that *Fosamax* causes AFFs and Mrs. Glynn’s *Fosamax* use caused her AFF.


1. Dr. Cornell Is Qualified as an Expert


Dr. Cornell is currently a Professor of Clinical Orthopedic Surgery at Weill Cornell College of Medicine and has been the Richard Laskin Chair in Orthopedic Surgery since 2011 [docket # 102, Ex. 8, Dr. Cornell’s Report (“Cornell Report”) at 2]. In addition, Dr. Cornell is an attending orthopedic surgeon at the Hospital for Special Surgery in New York City and currently serves as the hospital’s Director of the Department of Orthopedic Surgery. *Id.* He is a “specialist in orthopedic trauma ... and metabolic bone disease,” which includes osteoporosis and osteopenia [docket # 102, Ex. 10, Dr. Cornell’s Deposition (“Cornell Dep.”) at 69:13–16; 71:14–17]. About 80% of all the fractures Dr. Cornell treats surgically are fractures “as a consequence of osteoporosis or osteopenia.” *Id.* at 72:6–21. He has treated two patients with atypical fractures related to bisphosphonate use. Cornell Report at 3. Moreover, he has “participated in a study to determine a management strategy for the treatment of symptomatic bisphosphonate-associated incomplete atypical femoral fractures, which was peer reviewed and published in the Hospital for Special Surgery Journal.” *Id.* Although Defendant argues that Dr. Cornell is not qualified because he is not trained in epidemiology and is unfamiliar with “the most basic epidemiological terms and concepts” (Db13²), Dr. Cornell does not have to possess a particular subspecialty—epidemiology—to testify as an expert. See   *Schneider*, 320 F.3d at 406–07 (determining that testimony was improperly excluded because an individual “was not an expert in the sub-specialty about which he opined”);  *Holbrook v. Lykes Bros. S.S. Co., Inc.*, 80 F.3d 777, 783 (3d Cir.1996) (declaring that the lower court erred by requiring the expert to have a particular specialization and “exact background”); see also *Keller v. Feasterville Family Health Care Ctr.*, 557 F.Supp.2d 671, 675 (E.D.Pa.2008) (recognizing that expert testimony cannot be excluded because “the expert is without the appropriate specialization” and that “[a] certain degree of background is not required”). Because Dr. Cornell has the academic background and professional experience with osteoporosis, osteopenia, and fractures associated with those diseases, he is qualified to testify as an expert in this case. See   *Schneider*, 320 F.3d at 407.

2. Dr. Cornell’s Methodology Is Sufficiently Reliable

*3 Dr. Cornell formed his opinion using the Bradford Hill criteria, which are “nine factors widely used in the

scientific community to assess general causation.” *Gannon v. United States*, 292 Fed. Appx. 170, 173 (3d Cir.2008); Cornell Dep. at 329:5–8. General causation is when “an observed association between a chemical and a disease is causal.”

 *Magistrini v. One Hour Martinizing Dry Cleaning*, 180 F.Supp.2d 584, 592 (D.N.J.2002), *aff’d*, 68 Fed. Appx. 356 (3d Cir.2003). The nine Bradford Hill factors are: “1. Temporal Relationship, 2. Strength of the association, 3. Dose-response relationship, 4. Replication of the findings, 5. Biological plausibility (coherence with existing knowledge), 6. Consideration of alternative explanations, 7. Cessation of exposure, 8. Specificity of the association, and 9. Consistency with other knowledge.” FEDERAL JUDICIAL CENTER, REFERENCE MANUAL ON SCIENTIFIC EVIDENCE, at 599–600 (3d ed.2011), *available at* [http://www.fjc.gov/public/pd/fnsf/lookup/SciMan3D01.pdf/\\$file/SciMan3D01.pdf](http://www.fjc.gov/public/pd/fnsf/lookup/SciMan3D01.pdf/$file/SciMan3D01.pdf); *see also Gannon*, 292 Fed. Appx. at 173 n. 1; *In re Avandia Mktg., Sales Practices & Products Liab. Litig.*, 2011 WL 13576, *3 (E.D.Pa. Jan.4, 2011);

 *Magistrini*, 180 F.Supp.2d at 592–93. “[O]ne or more of the factors may be absent even where a causal relationship exists and ... no factor is a sine qua non of causation.


 *Magistrini*, 180 F.Supp.2d at 593 n. 9.


Dr. Cornell used the Bradford Hill criteria to form an opinion on whether Fosamax causes AFFs. Cornell Dep. at 331:4–8; Cornell Report at 4. In applying the nine Bradford Hill factors, he reviewed Plaintiff’s medical records from 1996 to present, the office notes and depositions of her treating physicians, and “past and current medical literature on the topics of osteopenia, osteoporosis and their prevention and treatment with bisphosphonate drugs including alendronate,” particularly publications concerning the FIT and FLEX studies and that described the appearance of AFFs. Cornell Report at 3, 4–5. He “review[ed] the original trials, the randomized trials, that led to the approval of Fosamax for the treatment of osteoporosis, and then wanted to review many of the case reports, the case series, the summed analysis, and some of the review papers that took all of this information and put it into a more readily digestible form.” Cornell Dep. at 56:13–23. Dr. Cornell attempted to “present a balanced analysis” and pointed out studies on both sides of the issue. *Id.* at 58:5–16. He concluded that Fosamax can cause AFFs and “Fosamax use was a substantial contributing factor to Mrs. Glynn’s femur fracture.” Cornell Report at 4. The methodology Dr. Cornell used is sufficiently reliable because the Bradford Hill criteria are “broadly accepted” in the scientific community “for evaluating causation,” *Gannon*,

292 Fed. Appx. at 173 n. 1, and “are so well established in epidemiological research,” *In re Avandia Mktg., Sales Practices & Products Liab. Litig.*, 2011 WL 13576, at *3.

*4 Defendant, however, argues that Plaintiffs do not explain the scientific methodology used by Dr. Cornell or show that his methodology is sufficiently reliable. Instead, Defendant asserts that Dr. Cornell’s “weight-of-the-evidence” methodology just lists some studies, only some of which support causation, and concludes that the weight of the evidence shows that Fosamax causes AFFs. Defendant explains that this method is inadequate because Dr. Cornell does not discuss how these studies establish causation or why certain studies outweigh others that do not find causation. Additionally, Defendant points out that Dr. Cornell has not done an evaluation of possible biases or confounding factors found in the studies. Because Dr. Cornell does not show that his methodology is sufficiently reliable to show general causation, Defendant argues that he cannot establish specific causation—that Mrs. Glynn’s Fosamax use caused her AFF. Defendant explains that the Bradford Hill criteria do not apply to specific causation, and Dr. Cornell’s differential diagnosis was unreliable because he did not rule out the possibility that other things could have caused Mrs. Glynn’s fracture.

Defendant is free to address these issues on cross-examination, but Defendant’s concerns do not prohibit Dr. Cornell from testifying as an expert because he is qualified and the methodology he used is sufficiently reliable. *See*

 *Milward v. Acuity Specialty Products Group, Inc.*, 639 F.3d 11, 15 (1st Cir.2011), *cert. denied*, — U.S. —, 132 S.Ct. 1002, 181 L.Ed.2d 734 (2012) (stating “*Daubert* does not require that a party who proffers expert testimony carry the burden of proving to the judge that the expert’s assessment of the situation is correct”; instead, the “proponent of the evidence must show only that ‘the expert’s conclusion has been arrived at in a scientifically sound and methodologically reliable fashion.’ ”).

Regarding Dr. Cornell’s specific causation opinion that Fosamax caused Mrs. Glynn’s femur fracture, he applied the differential diagnosis method, which is “a technique that involves assessing causation with respect to a particular individual.”  *Kannankeril v. Terminix Int’l, Inc.*, 128 F.3d 802, 807 (3d Cir.1997). It “is a process by which a physician rules out alternative causes through review of a patient’s medical histories and records, physical examination of the patient, laboratory testing, study of

relevant medical literature, and other techniques.” *In re Diet Drugs (Phentermine/Fenfluramine/Dexfenfluramine) Products Liab. Litig.*, 890 F.Supp.2d 552, 561 (E.D.Pa.2012). The “technique is generally accepted in the medical community.” *Id.*

Here, Dr. Cornell applied the differential diagnosis method by examining Mrs. Glynn's past medical history and conducting his own examination of her on September 26, 2012, after which he concluded that “[t]o a reasonable degree of medical certainty, Mrs. Glynn suffered a nontraumatic [AFF] in the setting of seven years of full dose Fosamax and alendronate therapy.” Cornell Report at 34–36. Dr. Cornell reviewed radiographs taken on April 17, 2009 to evaluate the fracture and reviewed follow-up X-rays, hospital records, rehabilitation records, orthopedics records, prescription records from pharmacies, and deposition transcripts, among other things, in forming his opinion [docket # 109, Ex. 78, Appendix B to Cornell Report]. He ruled out possible alternative causes of Mrs. Glynn's AFF. Cornell Report at 38–40, 42–43, 45–46. Dr. Cornell did not have to “rule out every possible alternative cause of” Mrs. Glynn's AFF; instead, only “[o]bvious alternative causes need to be ruled out.” *Heller v. Shaw Indus., Inc.*, 167 F.3d 146, 156 (3d Cir.1999). Thus, Dr. Cornell applied the differential diagnosis method in arriving at his conclusion that Mrs. Glynn's Fosamax use was a substantial contributing factor to her AFF.

*5 Therefore, the methodology used by Dr. Cornell in arriving at both his general and specific causation opinions is sufficiently reliable. Both the Bradford Hill criteria and differential diagnosis are widely used and accepted in the scientific community to arrive at causation opinions.

3. Dr. Cornell's Testimony Fits the Facts of the Case

Finally, Dr. Cornell's testimony fits the facts of the dispute and will assist the trier of fact because Plaintiffs seek to show that Mrs. Glynn's AFF was caused by her Fosamax use and Dr. Cornell not only opines that AFFs are caused by long term bisphosphonate use, like Fosamax, but also that Mrs. Glynn's Fosamax use was a “substantial contributing factor to her” AFF. *See* Cornell Report at p. 22, 47. Consequently, Dr. Cornell's proffered testimony will assist the trier of fact in determining whether Fosamax caused Mrs. Glynn's AFF.

Because Dr. Cornell is qualified, used a methodology that is sufficiently reliable, and his opinion fits the facts of a case, his expert testimony is admissible under *Daubert*.

B. Dr. Klein

Plaintiffs asked Dr. Klein, a pathologist, to offer his opinion on whether Fosamax use causes AFFs and the “mechanism by which those fractures are precipitated” [docket # 103, Ex. 11, Dr. Klein's Report (“Klein Report”) at 2].

1. Dr. Klein Is Qualified as an Expert

Dr. Klein is currently the Director of Pathology and Laboratory Medicine at the Hospital for Special Surgery where he has “direct clinical responsibilities for patients” *Id.* at 3–4. He also has “direct clinical responsibilities ... as a consultant at Memorial Sloan–Kettering Cancer Center, and as an outside counsel for leading pathology laboratories at major hospitals and institutions around the country.” *Id.* at 4. Dr. Klein has reviewed the pathology for at least four patients with AFFs [docket # 105, Ex. 37, Dr. Klein's Deposition (“Klein Dep.”) at 41:4–12]. Dr. Klein is currently a Professor of Pathology and Laboratory Medicine at Weill Cornell Medical College. Klein Report at 3. He is involved with several publications, including as the lead author and editor of *Non-neoplastic Diseases of Bones and Joints*, the only peer-reviewed, comprehensive textbook on the issue, and as a member of the editorial boards of *Human Pathology*, *Skeletal Radiology*, *Advances in Anatomical Pathology*, and *HSS Journal*. *Id.* Dr. Klein is the Consultant Editor of Research for *The Journal of Bone and Joint Surgery (American)* and has authored or co-authored more than 180 articles, most of which relate to bone pathology. *Id.* Therefore, Dr. Klein possesses “a broad range of knowledge, skills, and training” to qualify him as an expert in pathology. *In re Paoli*, 35 F.3d at 741.

2. Dr. Klein's Methodology Is Sufficiently Reliable

Like Dr. Cornell, Dr. Klein used the Bradford Hill criteria to form his opinion. Klein Report at 2. As discussed above, the Bradford Hill methodology is sufficiently reliable because it is “widely used in the scientific community to assess general causation.” *Gannon*, 292 Fed. Appx. at 173. In applying the nine Bradford Hill criteria, Dr. Klein reviewed human and animal studies and studies performed by Defendant to form his opinion. *See* Klein Report at 19–38. The studies revealed a strong association between bisphosphonates, like Fosamax, and microdamage in the bones as well as decreased bone toughness. *See id.* at 20, 25–30, 32. In addition, Dr. Klein noted a strong association between delayed fracture healing, due to altered bone quality, in patients and animals taking bisphosphonates. *Id.* at 23–24, 29. These findings

were replicated in several studies discussed in Dr. Klein's report. Moreover, Dr. Klein cited one study which recognized the “duration-dependent, as well as dose-dependent, effect bisphosphonates have on the skeleton.” *Id.* at 27. Another study mentioned in Dr. Klein's report noted that the “cessation of bisphosphonate treatment may be prudent for women on therapy who sustain a nonvertebral fracture.” *Id.* at 30. Thus, Dr. Klein applied the Bradford Hill criteria, including the strength of association, replication of findings, dose-response relationship, and cessation of exposure factors.

*6 Based on his review of the studies, Dr. Klein concluded that “alendronate significantly alters the cellular properties of bisphosphonate-treated bone.” *Id.* at 38. AFFs are not

attributed to low bone mass or osteoporosis alone, indicative of bone that has fundamentally compromised bone microstructure. Unless a damaging force exerts tension across the entire cortex, the laws of physics and biomechanics as applied to bone further support the conclusion that bone quality and microstructure must be fundamentally compromised for a transverse fracture in a hollow cylinder[, like the femur,] to follow.


[*Id.*]

Thus, Dr. Klein opined that there is a causal relationship between Fosamax and AFFs. *Id.* at 2. He used a sufficiently reliable methodology, the Bradford Hill criteria, in forming this opinion.

Defendant, however, argues that the Bradford Hill criteria apply to epidemiology studies, which Dr. Klein's report does not discuss. Defendant contends that Dr. Klein has not provided support for the proposition that a general causation conclusion can be established using the Bradford Hill criteria and human or animal biopsy data. In addition, Defendant asserts that if Dr. Klein discussed epidemiology studies in his report, he did not demonstrate that he is qualified to interpret that evidence because he has no expertise in epidemiology and does not understand the most basic epidemiology terms. Moreover, Defendant points out that Dr. Klein conceded that the mechanism regarding how bisphosphonates cause AFFs has not been established and that the theories Dr. Klein uses to support his conclusion about mechanism—microdamage, decrease in tissue heterogeneity, bone brittleness, and delayed healing—have not been proved with human data.

Yet, Dr. Klein has properly applied the Bradford Hill criteria to epidemiological studies. Epidemiological studies

include randomized trials in which one group is exposed to an agent, such as Fosamax, and another group is not, and the effect of the agent or lack thereof is observed. FEDERAL JUDICIAL CENTER, REFERENCE MANUAL ON SCIENTIFIC EVIDENCE at 555–56. Here, Dr. Klein examined randomized trials, such as Dempster et al., Boskey et al., and Donnelly et al.; in each of these studies, some women were given alendronate or another bisphosphonate and others were not. Klein Report at 20–21. Moreover, the Federal Judicial Center's Reference Manual on Scientific Evidence states that “toxicology models based on live animal studies ... may be used to determine toxicity in humans” in addition to observational epidemiology. FEDERAL JUDICIAL CENTER, REFERENCE MANUAL ON SCIENTIFIC EVIDENCE, at 563.

For his testimony to be admissible, Dr. Klein is not required to show that the mechanism has been definitely established. Instead, he just needs to show that the methodology he used to arrive at his opinion is sufficiently reliable. See  *Milward*, 639 F.3d at 15 (stating “*Daubert* does not require that a party who proffers expert testimony carry the burden of proving to the judge that the expert's assessment of the situation is correct”; instead, the “proponent of the evidence must show only that ‘the expert's conclusion has been arrived at in a scientifically sound and methodologically reliable fashion.’”). Dr. Klein arrived at his opinion on the mechanism by examining several studies and using a scientific method that is sufficiently reliable.

3. Dr. Klein's Testimony Fits the Facts of the Case

*7 Lastly, Dr. Klein's testimony fits the facts of the dispute and will assist the trier of fact. See *Jones*, 2010 WL 3311840, at *4. Through Dr. Klein's testimony, Plaintiffs seek to show that Fosamax causes AFFs and the mechanism by which this happens. See Klein Report at 2. Dr. Klein opines that Fosamax causes AFFs and discusses several ways this happens—microdamage, abnormal osteoclasts, altered bone quality, and delayed fracture healing. Thus, Dr. Klein's testimony will assist the trier of fact in determining whether Fosamax causes AFFs, the ways in which this happens, and ultimately, his testimony will aid the jury in deciding whether Mrs. Glynn's Fosamax use caused her AFF.


C. Dr. Madigan

Plaintiffs asked Dr. Madigan, a statistician, to give his opinion regarding “whether a signal of problematic oversuppression

of bone turnover and associated [AFF] ... existed for Fosamax, using industry standard pharmacovigilance techniques and data sources, and the adverse event terms selected by Merck to internally evaluate the same” and “assess the strength of that signal, if any, in comparison to the signal, if any, for such events in other products indicated for the prevention and treatment of osteoporosis” [docket # 33, Ex. 30, Dr. Madigan's Report (“Madigan Report”) at ¶ 5].

1. Dr. Madigan Is Qualified as an Expert

Dr. Madigan is Professor and Chair of Statistics at Columbia University. *Id.* at ¶ 1. He is an elected Fellow of the Institute of Mathematical Statistics and the American Statistical Association, and from 1995 to 2005 was the 36th most cited mathematician worldwide. *Id.* In 2010, he completed a term as Editor of the journal *Statistical Science*. *Id.* Dr. Madigan has consulted for companies such as Novartis, Pfizer, and Sanofi–Aventis on several issues, “many related to drug safety.” *Id.* at ¶ 2. He has statistical experience with clinical trials and has published more than 100 technical papers on many topics, including pharmacovigilance³. *Id.*

Within the last few years, drug safety “with a focus on the development and application of statistical methods for pharmacovigilance” has been “one of [Dr. Madigan's] significant research interests” *Id.* at ¶ 3. He has published work in several journals, including *Drug Safety*, *Pharmacoepidemiology and Drug Safety*, and *Epidemiology*. *Id.* Dr. Madigan is an investigator in the Mini–Sentinel project, which is “a pilot project sponsored by the FDA to inform and facilitate development of a fully operational active surveillance system, the Sentinel System, for monitoring the safety of FDA-regulated medical products.” *Id.* He is the “methods lead for the Observational Medical Outcomes Partnership, a public-private partnership between the FDA and the pharmaceutical industry, which addresses “research methods that are feasible and useful to analyze existing healthcare databases to identify and evaluate safety and benefit issues of drugs already on the market.” *Id.* Dr. Madigan is a member of the FDA's Drug Safety and Risk Management Committee, which “advises the FDA Commissioner on risk management, risk communication, and quantitative evaluation of spontaneous reports for drugs for human use and for any other product for which the FDA has regulatory responsibility.” *Id.* Dr. Madigan is qualified as an expert because he has “a broad range of knowledge, skills, and training [to] qualify ... [him] as such.”  *In re Paoli*,

35 F.3d at 741. Defendant does not dispute Dr. Madigan's qualifications.


2. Dr. Madigan's Methodology Is Sufficiently Reliable

*8 Dr. Madigan examined the FDA's Adverse Event Reporting System (“AERS”) database for a “possible association between Fosamax and a series of ... terms selected by Merck to evaluate oversuppression of bone turnover and associated” AFFs. Madigan Report at ¶ 25. The terms were: bone development abnormal, bone disorder, bone formation decreased, fracture delayed union, fracture malunion, fracture nonunion, low turnover osteopathy, pathological fracture, stress fracture, fracture, and femur fracture. *Id.* at ¶ 26. Dr. Madigan used “two industry-standard signal detection algorithms ... to assess whether or not Fosamax presented a safety signal” indicating oversuppression of bone turnover or AFFs. *Id.* at ¶ 25. The QScan pharmacovigilance software computed the statistics. *Id.* at ¶ 27. Dr. Madigan then compared the Fosamax signals to other oral bisphosphonates and a non-bisphosphonate used for the treatment and prevention of osteoporosis. *Id.* at ¶ 25. After reviewing the data, Dr. Madigan opined that

industry standard pharmacovigilance techniques and datasources reveal the presence of a clear signal for oversuppression of bone turnover and associated atypical femur fracture events utilizing the terms selected by Merck for such analysis. By standard metrics of “signal” detection, the signal is strong, consistent, and not ambiguous. Of perhaps greater concern, the signal was striking in comparison to that for other drugs indicated for the prevention and treatment of osteoporosis. As early as 2001–2002, the spontaneous report data for Fosamax provide signals for a number of indicators of suppression of bone turnover. For the comparator drugs, such signals either never appear or appear years later.

[*Id.* at ¶ 36.]


This opinion is admissible because it is based on a method that is sufficiently reliable. See *Jones*, 2010 WL 3311840, at *4. Two factors that a court may take into consideration in determining reliability is whether the methodology has been subjected to peer review and publication and whether there is general acceptance in the scientific community.

 *Daubert*, 509 U.S. at 593–94. Here, Dr. Madigan's method, data mining in pharmacovigilance, is generally accepted in the scientific community and has “become routine both in the pharmaceutical industry and amongst regulators worldwide.”

Madigan Report at ¶ 8. In fact, “[p]harmaceutical companies, health authorities, and drug monitoring centers use SRS databases for global screening for signals of new adverse events or changes in the frequency, character, or severity of existing adverse events (AEs) after regulatory authorization for use in clinical practice.” *Id.* at ¶ 9. “SRS systems provide the primary data for day-to-day drug safety surveillance by regulators and manufacturers worldwide.” *Id.* at ¶ 14. In addition, the QScan software Dr. Madigan used in formulating his opinion is generally accepted by the scientific community because it “has been in widespread use for over 10 years and has been validated extensively.” *Id.* at ¶ 28. Moreover, “[m]any peer-reviewed publications report results derived from QScan.” *Id.* Thus, Dr. Madigan's methodology is sufficiently reliable.

*9 Although Defendant argues that Dr. Madigan's methodology is unreliable because he did not review the substance of the adverse event reports to see if they actually involve AFFs or oversuppression of bone turnover, this argument is inappropriate on a *Daubert* motion. Dr. Madigan's testimony will be subject to cross-examination, and the credibility of his opinion will be ultimately determined through the adversarial process. Dr. Madigan's methodology is sufficiently reliable because it is generally accepted in the scientific community, and therefore, Plaintiffs have satisfied the second prong of *Daubert*.

3. Dr. Madigan's Testimony Fits the Facts of the Case

Lastly, Dr. Madigan's testimony fits the facts of the case and will assist the trier of fact because it is related to Plaintiffs' failure to warn claim. *See Jones*, 2010 WL 3311840, at *4. A failure to warn claim requires a plaintiff to show “(1) that a manufacturer has a duty to warn (2) against dangers resulting from foreseeable uses about which it knew or should have known and (3) that failure to do so was the proximate cause of the harm.”  *In re Fosamax Prods. Liab. Litig.*, 2013 WL 76140, *3 (S.D.N.Y. Jan. 7, 2013). Dr. Madigan's testimony fits the facts of this case because he opines that “[a]s early as 2001–2002, the spontaneous report data for Fosamax provide[d] signals for a number of indicators of suppression of bone turnover,” meaning Defendant knew or should have known that Fosamax caused certain dangers in 2001–2002, thus imposing on Defendant a duty to warn of those dangers. Madigan Report at ¶ 36.

Defendant, however, argues that Dr. Madigan's testimony does not fit the facts of the case because it is irrelevant

since there is no reasonable standard of care that would have required Defendant to conduct data mining. This is also a matter best left to the credibility determination of the jury.


As a result, Dr. Madigan's expert testimony is admissible under *Daubert* because he is qualified, he used a sufficiently reliable methodology, and his opinion fits the facts of the case.

D. Dr. Blume


Dr. Blume is offered as an expert in pharmacovigilance and FDA regulation. Plaintiffs offer the testimony of Dr. Blume to: (1) “address the timeliness and completeness of the efforts undertaken by [Defendant] ... to fully inform prescribers and patients of the increasingly adverse benefit risk assessments associated with long-term Fosamax use in postmenopausal women”; (2) “evaluate the negative consequences of protracted bone oversuppression,” including AFFs, in people receiving Fosamax; and (3) “to consider the pharmacovigilance activities undertaken by [Defendant] to evaluate the noted adverse events during the relevant time periods” [docket # 119, Ex. 33, Dr. Blume's Report (“Blume Report”) at ¶ 6].

1. Dr. Blume is Qualified as an Expert

Dr. Blume received her Ph.D. in Pharmacology and Toxicology from the West Virginia University Medical Center and is currently the President of Pharmaceutical Development Group, Inc. (PDG), “a consulting firm ... specializing in pharmaceutical development and registration activities.” *Id.* at ¶ 1. In this role, she “has been responsible for preclinical and clinical (Phases I–IV) programs associated with pharmaceutical product development and the securing of pre-marketing approvals” for many drugs before the FDA. *Id.* at ¶ 2. Additionally, Dr. Blume has directed “all phases of interactions with [the] FDA relating to the prosecution of New Drug Applications (NDAs), Abbreviated New Drug Applications (ANDAs), Supplements to New Drug Applications (sNDAs), and the associated approval procedures,” including “the collection and evaluation of postmarketing adverse medical events, the preparation of updated product labeling, and the dissemination of accurate, complete and timely product-related information to health care providers.” *Id.* at ¶ 3. She was responsible for “regulatory review of promotional and education materials for both brand-name and generic drug products.” *Id.* Dr. Blume's responsibilities include the “design, execution, and interpretation of pivotal safety-related trials and the development and implementation of pharmacovigilance

procedures intended to detect new safety signals and track the evolution of previously identified signals.” *Id.* at ¶ 4. She has directed “all phases of interactions with the FDA relating to post-approval labeling procedures regarding changes to safety-related information based upon postmarketing signal tracking and pharmacovigilance efforts,” including “collection and evaluation of postmarketing adverse medical events, review and interpretation of the results of postmarketing clinical studies, the preparation of updated product labeling and other communication tools, and the dissemination of new product information to health care providers, patients, and consumers.” *Id.* at ¶ 5. Dr. Blume possesses the knowledge, skills, and training necessary to qualify her as an expert. See  *In re Paoli*, 35 F.3d at 741. Defendant does not dispute Dr. Blume's qualifications.

2. Dr. Blume's Methodology Is Sufficiently Reliable


*10 Dr. Blume reviewed published studies (Blume Report at ¶¶ 57–74), Merck's Period Safety Update Reports (*id.* at ¶ 75), Dr. Madigan's report (*id.* at ¶¶ 76–78), Merck's Worldwide Adverse Experience System (“WAES”) (*id.* at ¶ 79), and epidemiological studies (*id.* at ¶¶ 82–90). See also docket # 119, Ex. 5, Dr. Blume's Deposition (“Blume Dep.”) at 148:9–18; 338:9–20 (stating that she looked at the WAES database, literature reports, epidemiological studies, the AERS database, and Dr. Madigan's report). She discussed the “specific regulatory procedures and regulations” pharmaceutical manufacturers have to comply with, including procedures and regulations related to FDA approval, labeling, postmarketing surveillance, and reporting requirements. *Id.* at ¶¶ 11–34. Dr. Blume evaluated all of this information using “her years of experience” in “the industry,” see  *In re Viagra Products Liability Litigation*, 658 F.Supp.2d 950, 962 (D.Minn.2009), and opined that

the scientific literature, Merck's internal adverse event database, the AERS database, and epidemiology analyses confirmed the increasingly adverse risk-benefit profile related to long-term Fosamax use in the indicated populations. However, Merck permitted their labeling and other prescriber information to remain static with respect to both the deteriorating risk-benefit assessment and the escalation in ... [AFF] reports. Such omissions do not comply with the regulatory and industry standards of responsible pharmaceutical companies Merck also should have undertaken timely and adequate studies to more clearly elucidate the risks of Fosamax use in the various indicated populations. Finally, Merck should

have disseminated Dear Healthcare Professional Letters to advise prescribers and their patients of the escalating safety and efficacy concerns. Merck's omissions have likely resulted in the exposure of numerous patient populations to unnecessary risks associated with the initiation and ongoing treatment with Fosamax.

[Blume Report at ¶ 110.]


Dr. Blume states that “[b]y the early 2000's, it was known that ... [AFFs] were clinically significant events” *Id.* at ¶ 109. Dr. Blume opines that Defendant should have changed the Fosamax label “to include escalating warning and precautionary risk information related to” AFFs. *Id.* Instead, Dr. Blume notes that Defendant “did not identify these fractures in the labeling until 2009” even though it received reports that AFFs were “associated with Fosamax use as early as 2002.” *Id.* at ¶¶ 31, 82.

Defendant argues that the Court should exclude Dr. Blume's opinions on: (1) the legal requirements governing pharmaceutical manufacturers and Defendant's compliance with those requirements; (2) Defendant waiting too long to add information about femur fractures to the Adverse Reactions section of the label; (3) Defendant failing to add a warning or precaution about femur fractures to the Fosamax label before 2009; (4) Defendant's failure to timely investigate a potential link between Fosamax and AFF; (5) Defendant's alleged motives or state of mind; (6) the causation or mechanism of AFF; and (7) the drug Evista is safer than Fosamax. Yet, because *Daubert* concerns the narrow issue of whether expert testimony is admissible, this is not the appropriate time for Defendant to request that the Court preclude Dr. Blume from testifying about certain topics. Defendant may question Dr. Blume's opinions or methodology on cross-examination. See  *Milward*, 639 F.3d at 15 (stating “[s]o long as an expert's scientific testimony rests upon “good grounds,” based on what is known, ..., it should be tested by the adversarial process, rather than excluded”).

*11 Despite Defendant's issues with Dr. Blume's opinions, Plaintiffs have satisfied the second prong of *Daubert* because Dr. Blume's methodology is sufficiently reliable.


3. Dr. Blume's Testimony Fits the Facts of the Case

Dr. Blume's testimony fits the facts of the case because she opines that it was known in the early 2000's that AFFs were associated with Fosamax use. See Blume Report at ¶¶ 31, 82.

Dr. Blume's testimony is relevant and will assist the trier of fact in deciding Plaintiffs' failure to warn claim because Dr. Blume's opinion is relevant to whether and when Defendant knew or should have known that AFFs were associated with Fosamax and therefore, when Defendant should have sought a label change. See  *Schneider*, 320 F.3d at 404 (recognizing that expert testimony must "be relevant for the purposes of the case and must assist the trier of fact").

E. Treating Physicians

Defendant argues that the Court should preclude causation testimony from Plaintiffs' treating physicians—Drs. Busch, Lindsay, Fletcher, and Limes—because: (1) Plaintiffs have not provided Rule 26 disclosures for any of the treating physicians; and (2) none of the treating physicians are able to offer a reliable causation opinion to a reasonable degree of medical certainty. Plaintiffs, however, assert that they do not intend to elicit expert testimony from the treating physicians; instead, the treating physicians will testify about Mrs. Glynn's care and treatment, which does not require Rule 26 disclosures.

Treating "physicians are not required to submit expert reports when testifying based on their examination, diagnosis and treatment of a patient."  *Patterson v. Howard*, 2010 WL 1050052, *4 (D.N.J. Mar.18, 2010). Federal Rule of Civil Procedure 26(a)(2)(B) requires a witness to submit a written report only "if the witness is one retained or specially employed to provide expert testimony in the case or one whose duties as the party's employee regularly involve giving

expert testimony." A "treating physician is not necessarily retained or specially employed to provide expert testimony simply because he or she proffers on causation and prognosis" because "doctors may need to determine the cause of an injury in order to treat it." *Pease v. Lycoming Engines*, 2012 WL 162551, *12 (M.D.Pa. Jan.19, 2012). In order to "determine whether a party retained or specially employed a treating physician to provide expert testimony," the Court must examine "whether the treating physician acquired his opinion as to the cause of ... plaintiff's injuries directly through his treatment of the plaintiff." *Id.* (internal quotation omitted). As a result, treating physicians are not required to submit expert reports "if they form their opinion on causation or prognosis as part of the ordinary care of a patient." *Id.*

Therefore, the testimony of Drs. Busch, Lindsay, Fletcher, and Limes is appropriate if it is based on their care and treatment of Mrs. Glynn. This Court will not allow, however, any expert testimony on causation from these physicians.

II. CONCLUSION

*12 For the reasons outlined above, this Court denies Defendant's *Daubert* Motion as to Drs. Cornell, Klein, Madigan, and Blume. An appropriate Order accompanies this Opinion.

All Citations

Not Reported in F.Supp.2d, 2013 WL 1558690, 91 Fed. R. Evid. Serv. 106

Footnotes

- 1 The abbreviation of atypical femur fracture (singular) is "AFF."
- 2 Db13 means page 13 of Defendant's brief.
- 3 Pharmacovigilance is the surveillance of spontaneous reporting system ("SRS") databases "for the early detection of drug hazards that are novel by virtue of their clinical nature, severity, and/or frequency." *Id.* at ¶ 7.